[DOI] [PMC free article] [PubMed] [Google Scholar] [111].Davies MJ, Bergenstal R, Bode B, et al
Research from Harvard found that non-diabetic users, people taking the drug purely for weight loss, faced the highest risk
Slowing Gastric Emptying By slowing the stomachs emptying process, these medications promote a feeling of fullness
Zepbound Originally marketed as Monjaro for Type 2 Diabetics, it was rebranded as Zepbound for weight loss when studies showed that 90% of patients lost 20% or more of their starting body weight
People who benefit most typically have a BMI of 30 or higher, or a BMI of 27 or higher with weight-related health conditions like high blood pressure
Refunded in full if it's not right for you